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Abstract
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)- Outcome 
Measures in Rheumatology (OMERACT) PsA Core Set working group recently published the 
updated 2016 psoriatic arthritis (PsA) core domain set, a set of disease features that should be 
measured in all clinical trials. At the GRAPPA annual meeting in July 2016, the PsA working 
group presented the updated PsA core domain set endorsed by 90% of participants at OMERACT 
in May 2016 and held a working group meeting where the working group drafted a roadmap for 
the development of the PsA core outcome measurement set. In this manuscript, we review the 
development process of the PsA core domain set and the ongoing and proposed workstreams for 
development of a PsA core measurement set.
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Outcome measure development has rapidly progressed over the past 10 years and so too has 
our knowledge of psoriatic arthritis (PsA) pathophysiology and the multiple facets of life 
impacted by this disease.(1, 2) The Group for Research and Assessment of Psoriasis and 
Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) PsA 
working group developed a Core Domain Set to be measured in randomized controlled trials 
(RCTs) and longitudinal observational studies (LOS), and is working to develop a Core 
Outcome Measurement Set. At the GRAPPA annual meeting in July 2016, the working 
group presented results and next steps.
PsA Updated Core Domain Set
The PsA working group includes an international group of rheumatologists, dermatologists, 
patient research partners (PRPs), methodologists, and two fellows. The working group 
developed a plan to update the 2006 PsA Core Domain Set (3) following the OMERACT 
meeting in May 2014.(4) At that meeting, OMERACT participants voted that the PsA core 
domain set should be revised given updated knowledge about PsA (including the importance 
of individual disease manifestations), the need to incorporate patient input, and new 
OMERACT “Filter 2.0” methodology (a set of guidelines proposed by OMERACT for 
development of core domain sets).(5) The group developed a plan to address these issues 
through individual workstreams that culminated in a series of consensus activities. PRPs 
were included in all phases including one PRP on the steering committee, and at least one 
PRP was involved in the planning and interpretation of each of the workstreams.(6, 7)
Using the OMERACT Filter 2.0 framework, the working group performed an update (2010–
2015) of the systematic literature review of domains measured in RCTs and LOS.(8) Next, 
patient domains were identified through international focus groups (130 patients in 7 
countries). A total of 39 domains were identified from focus groups and literature review. In 
a phone conference, the working group discussed how to organize and describe these 39 
domains in patients’ words. Patient and provider Delphi surveys were then sent to 75 
patients and 125 physicians (rheumatologists and dermatologists) to rate the importance of 
the items for measurement in RCTs and LOS. These data formed the basis for a group 
discussion at a Nominal Group Technique meeting held in Jersey City, NJ, in March 2016. 
Twelve PRPs and twelve physicians came to consensus on a preliminary core domain set 
through a moderated discussion. The preliminary core domain set was then proposed at the 
OMERACT meeting in Whistler, British Columbia, in May 2016. The final core domain set 
(Figure 1) includes three parts: an inner circle (should be measured in all RCTs and LOS), a 
middle circle (important but not mandatory), and the outer circle that represents the research 
agenda. The inner circle includes musculoskeletal (MSK) disease activity (peripheral 
arthritis, enthesitis, dactylitis, and spine symptoms), skin disease activity (skin psoriasis and 
nail dystrophy), pain, patient global, physical function, health related quality of life, fatigue, 
and systemic inflammation. The middle circle includes economic cost, emotional well-
being, participation, and structural damage. Finally, stiffness, independence, treatment 
burden, and sleep are in the research agenda. Some domains included in the 2016 core 
domain set were also present in the 2006 and 2014 Core Domain Sets, some moved from the 
outer circle, and others were added (Figure 1 shows these changes).
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Having achieved ratification of the core domain set, the next step for the PsA working group 
is to select outcome measurement instruments. One of the issues raised at OMERACT and 
again at the GRAPPA meeting was the number of domains included within the core domain 
set. The feasibility of capturing the full set even within the inner circle is a daunting task. It 
is important to recognize that each domain will not necessarily need to be measured by an 
individual instrument. Most recent RCTs are already measuring these domains.(8) In fact, 
among the eight most recently conducted RCTs, most of these domains were captured 
although fatigue, participation, and spine symptoms are less commonly measured (Table 1).
PsA Core Set working group meeting
During this meeting, the working group discussed and reviewed organization of workstreams 
to tackle development of the PsA Core Outcome Measurement Set (Figure 2). Each 
workstream includes at least two PRPs. A series of systematic literature reviews are ongoing 
to assess measurement properties of candidate instruments including patient-reported 
outcomes assessing skin and joint disease activity, fatigue, pain, patient global, health-
related quality of life, participation, and emotional well-being; physical examination 
methods for assessing MSK and skin disease activity; systemic inflammation; imaging 
modalities to assess structural damage and disease activity; and composite disease activity 
measures. A qualitative assessment of the feasibility and the content validity of available 
instruments from the perspective of patients and physicians has been launched. 
Simultaneously, instrument assessments are being performed within RCTs and LOS. These 
three efforts will produce data about the measurement performance of each instrument. 
These data will be presented and discussed in a workshop and breakout groups at the next 
GRAPPA annual meeting, after which the group may realize that additional data are needed. 
The working group will then refine the data obtained and structure the patient and physician 
Delphi surveys using similar methods to those used in the development of the core domain 
set. The patient and physician Delphis will be used to achieve consensus on the optimal 
instruments to address some, if not all, of the core domains. If needed, an in-person 
consensus meeting will be held following the Delphi. The working group aims to present a 
preliminary core outcome measurement set for discussion and voting at the next OMERACT 
meeting in May 2018.
Conclusion
As the number of new therapies for psoriasis and PsA increases, the need to understand how 
to best measure disease activity, impact and long-term patient outcomes has become more 
important. Additionally, standardizing outcome measurement among RCTs and LOS will 
assist patients, clinicians, and other stakeholders in better evaluating the evidence available 
for a particular treatment. To this end, patients, rheumatologists, dermatologists, and 
methodologists are working together through GRAPPA, OMERACT, and the International 
Dermatology Outcome Measurers (IDEOM) to develop and standardize core outcome 
measurement sets for psoriatic disease.
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Figure 1. 2006 and 2016 GRAPPA-OMERACT PsA Core Domain Sets
In the 2016 core domain set (right), domains that moved from one of the outer circles to 
either the middle or inner circle are noted with an asterisk. MSK disease activity (now 
includes peripheral arthritis, enthesitis, dactylitis, and spine symptoms) and skin disease 
activity (psoriasis and nail dystrophy) were redefined (marked with “†”). Finally, items 
marked with “‡” are new additions to the set. This figure was modified from Figure 3 in 
Orbai et al. Ann Rheum Dis 2016 with permission.
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Figure 2. Roadmap for developing the Psoriatic Arthritis (PsA) Core Outcome Measurement Set
Workstreams are listed in chronological order.
GRAPPA = Group for Research and Assessment of Psoriasis and Psoriatic Arthritis;
OMERACT = Outcome Measures in Rheumatology; WG = working group;
LOS = longitudinal observational studies; OMIs = outcome measurement instruments;
RCT = randomized controlled trials; SLR: systematic literature review.
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